SecBot SecBot
SECBOTREPLAY Home › Report › SKYE

SKYE · Skye Bioscience has dosed the first patient in the Part C expansion of…

Skye Bioscience, Inc. · PRESS-RELEASE filed Apr 2, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Apr 2, 2026 at 07:00 ET

Skye Bioscience has dosed the first patient in the Part C expansion of its Phase 2a trial for nimacimab, testing higher IV doses (400 mg and 600 mg) to evaluate improved peripheral exposure and safety. The company highlighted strong prior results from combination therapy with semaglutide, showing 22.3% mean weight loss at 52 weeks, and received FDA feedback on its proposed Phase 2b design, though trial progression depends on Part C data and capital availability.

  • First patient dosed in Part C expansion study of nimacimab Phase 2a trial, testing 400 mg IV and 600 mg IV doses.
  • Higher doses correspond to ~700 mg and ~1,000 mg subcutaneous dosing, aiming for greater peripheral tissue exposure.
  • Prior combination data with semaglutide showed 22.3% mean weight loss at 52 weeks, no plateau, and reduced weight regain off-treatment.
  • No drug-related neuropsychiatric adverse events reported in any arm through full study period.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access